Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624000895583
Ethics application status
Approved
Date submitted
5/07/2024
Date registered
22/07/2024
Date last updated
8/09/2024
Date data sharing statement initially provided
22/07/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Ketamine-assisted psychotherapy for methamphetamine use disorder
Query!
Scientific title
An open-label safety and feasibility pilot trial of ketamine-assisted psychotherapy for methamphetamine use disorder in adults
Query!
Secondary ID [1]
312469
0
None
Query!
Universal Trial Number (UTN)
U1111-1312-8045
Query!
Trial acronym
KAPPA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Addiction
334307
0
Query!
Methamphetamine use disorder
334308
0
Query!
Condition category
Condition code
Mental Health
330963
330963
0
0
Query!
Addiction
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The intervention consists of four sessions (1:1, face-to-face) of psychotherapy (cognitive behavioural therapy; CBT) over four weeks with adjuvant ketamine in the 24 to 48 hours prior to the second, third and fourth sessions.
1. CBT
The routine 4-session manualised Cognitive Behavioural Therapy (CBT) program developed by Baker et al (2003) will be provided by trained therapists to all participants in the trial. The broad content and aims of each session are outlined below, with sessions lasting approximately 1.5 hours each:
Session 1 - Motivational interviewing. Key aims of this session: engagement and building motivation for change in relation to methamphetamine (MA) use, preparing to reduce MA use, and introduction to behavioural self-monitoring.
Session 2 - Coping with cravings and lapses. Key aims of this session: reinforcing motivation to maintain abstinence/reduced level of use, coping with cravings to use, preparing for a lapse.
Session 3 - Controlling thoughts about amphetamine use and pleasurable activities. Key aims of this session: introduction to the concept that thoughts influence behaviour, developing a plan of achievement and pleasurable tasks to carry out through the week, and continuing to cut down/maintain abstinence.
Session 4 - Amphetamine refusal skills and preparation for future high-risk situations. Key aims of this session: learning and practicing MA refusal skills, identifying potential high-risk situations that may occur in the future, developing a specific relapse prevention/relapse management plan for anticipated high-risk situation, encouraging use of relapse prevention/relapse management plan to prevent use of MA, learning how to deal with a lapse.
Therapists are defined as staff with graduate qualifications in a relevant health discipline (such as counselling, nursing, social work, psychology, psychiatry), including trainees with adequate skills, that have undergone training on the use of the manual. Therapists will be trained by a senior psychologist with expertise in CBT for MAUD. Training will be face-to-face, delivered during a workshop, at least 1 week prior to the first participant enrolment. Session checklists will be completed post-session by the therapist to assess treatment fidelity and discussed during group supervision with a senior psychologist. As per Baker et al (2003), study participants will be encouraged to complete homework tasks in-between sessions. Therapists will also be certified in ICH-GCP.
The initial assessment will take place as part of CBT session 1, covering: (1) alcohol and other drug use history, (2) mental health assessment, (3) client’s readiness to change MA use. Information about what will happen during the first ketamine dose session will be provided.
One week later, a preparation session will be undertaken immediately prior to ketamine dose 1. Psychological preparation and pre-infusion relaxation exercises will be given, and participants be briefed on what to expect during the ketamine dose along with a discharge information sheet.
Within 24-48 hours of ketamine dose 1, CBT session 2 will be undertaken, guided initially by an integration session where experiences of the ketamine session will be briefly explored. This approach will be used for the remaining sessions.
Therapists will coordinate the four sessions to occur at least one week apart. Session 1 will occur during week 1; Sessions 2, 3 and 4 will occur during weeks 2,3 and 4 respectively within 24-48 hours of participants receiving study medication. An optional one-hour 'booster’ session with the therapist will be offered at week 6. CBT session attendance will be used to monitor adherence to the intervention.
2. Medication
The medication under investigation is the TGA approved ketamine hydrochloride 200mg/ml, commercially available and branded in Australia formulated in liquid solution for intravenous and intramuscular injection as an anaesthetic agent. It has also been administered subcutaneously in the sub-anaesthetic doses used in study trials for TRD (Loo et al., 2016, 2023). A total of three subcutaneous doses, at least 7 days apart, will be administered by a registered nurse, once weekly during Weeks 2, 3 and 4. An increasing dose regimen will be used as follows:
- Dose 1: 0.75mg/kg
- Dose 2: if dose 1 well tolerated, increase to 0.9mg/kg. If dose 1 moderately tolerated, reduce to 0.75mg mg/kg. If dose 1 poorly tolerated, reduce to 0.6mg/kg.
- Dose 3: dose range 0.5mg/kg to 0.9mg/kg depending on tolerability of dose 2.
Direct observation will be used to monitor adherence to the intervention.
Query!
Intervention code [1]
328986
0
Treatment: Other
Query!
Intervention code [2]
329057
0
Treatment: Drugs
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
338731
0
Safety will be monitored by study staff conducting weekly clinic visits, with oversight from the site Principal Investigator. All safety measures will be assessed as a primary composite outcome. Safety data will be collected through Adverse Event and Serious Adverse Event reporting, and a Data Safety and Monitoring Board (DSMB) will be convened to review accumulating data. The incidence of adverse events (AEs) will be recorded across the duration of the study, by system organ class (SOC), including the number of participants with AEs of vital signs recorded outside expected limits. The primary safety measure is the number of treatment-emergent AEs by SOC, described by seriousness, severity, causality and expectedness (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Annotated with TGA Comments, 2016; National Health and Medical Research Council, 2016). Adverse events will be documented at each clinic visit. Subjective descriptions of AEs provided by participants will be transcribed verbatim and reported in accordance with the Medical Dictionary for Regulatory Activities (MedDRA) terminology, developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Severity will be graded from Grade 1 (mild) to Grade 5 (death) by the site Principal Investigator (U.S. Department of Health and Human Services, 2017). Causality will be determined by the site Principal Investigator, and expectedness in accordance with international guidelines and Australian product labels for ketamine hydrochloride 200mg/ml for injection (Baxter, 2020; Pfizer, 2021). Any known reaction listed on the product label will be considered potentially causally related. Adverse events will be elicited through structured assessment with the Ketamine Side-Effects Tool (KSET) (Bayes et al, 2022). Additional safety measures will be reported descriptively including:
- Blood pressure and heart rate trends
- Dissociative effects
- Suicidality
- Non-medical use liability
- Changes in other drug use (including ketamine)
Query!
Assessment method [1]
338731
0
- Structured assessment of adverse events as measured by the Ketamine Side-Effects Tool (KSET)
- Dissociative effects as measured by the Clinician Administered Dissociative States Scale (CADSS-6)
- Elevated mood effects as measured by the Young Mania Rating Scale (YMRS; item 1)
- Suicidality as assessed with the Columbia Suicide Severity Rating Scale (C-SSRS)
- Non-medical use liability as measured by Drug Experiences Questionnaire (DEQ-5)
- Changes in other drug use (including ketamine) as measured by Timeline Follow Back (TLFB )
Query!
Timepoint [1]
338731
0
Assessments will be conducted weekly during Weeks 1-4, post-treatment (Week 5), primary endpoint (end of Week 8), and two follow-up points (Week 12, Week 24).
Query!
Primary outcome [2]
338732
0
Feasibility. All feasibility measures will be assessed as a primary composite outcome.
Query!
Assessment method [2]
338732
0
- Time taken to recruit entire sample (number of weeks between recruitment of participant 1 to recruitment of participant 20)
- Proportion of ineligible participants at pre-screening and screening (assessed at study end through audit of pre-screening and screening logs)
- Number of participants who receive 3 doses of ketamine
- Number of participants who complete 4 sessions of CBT
- Number of participants attending optional booster CBT session
- Retention rate over the full duration of the study (assessed at study end through audit of study records - number of participants attending each clinic visit)
- Qualitative interview: optional semi-structured, one-on-one interviews of approximately 1 hour, examining the themes of expectation and expectation management, experience of participating in the trial, thoughts on how the trial could be improved in the future, experience of psychological sessions, any general concerns around subcutaneously administered ketamine, and how the potential addition of a placebo or active control may change their perspectives.
Query!
Timepoint [2]
338732
0
All feasibility outcomes will be assessed upon conclusion of the study (i.e. the end of Week 24). Qualitative interviews will be conducted during Weeks 5 - 8.
Query!
Secondary outcome [1]
437223
0
Self-reported change in past 28-days of methamphetamine use
Query!
Assessment method [1]
437223
0
Timeline Follow Back (TLFB)
Query!
Timepoint [1]
437223
0
Weekly from baseline to Week 5 (post treatment), then at Week 8, Week 12 and Week 24 post intervention commencement,
Query!
Secondary outcome [2]
437226
0
Presence of methamphetamine in urine
Query!
Assessment method [2]
437226
0
Point of care (POC) urine drug screen (UDS)
Query!
Timepoint [2]
437226
0
Weekly from baseline to Week 5, then at Week 8, Week 12 and Week 24 post intervention commencement.
Query!
Secondary outcome [3]
437227
0
Changes in methamphetamine craving
Query!
Assessment method [3]
437227
0
Visual Analogue Scale - Craving (VAS-C)
Query!
Timepoint [3]
437227
0
Weekly from baseline to Week 5, then at Week 8, Week 12 and Week 24 post intervention commencement
Query!
Secondary outcome [4]
437228
0
Changes in methamphetamine withdrawal symptoms
Query!
Assessment method [4]
437228
0
Amphetamine Withdrawal Questionnaire (AWQ)
Query!
Timepoint [4]
437228
0
At baseline, then at Week 5, Week 8, Week 12 and Week 24 post intervention commencement
Query!
Secondary outcome [5]
437229
0
Changes in quality of life
Query!
Assessment method [5]
437229
0
World Health Organisation Quality of Life Scale - Brief Version (WHOQOL-BREF)
Query!
Timepoint [5]
437229
0
At baseline, then at Week 5, Week 8, Week 12 and Week 24 post intervention commencement
Query!
Secondary outcome [6]
437230
0
Treatment satisfaction
Query!
Assessment method [6]
437230
0
Treatment Satisfaction Questionnaire for Medication Version II (TSQM-II)
Query!
Timepoint [6]
437230
0
Week 5, Week 8 post intervention commencement
Query!
Secondary outcome [7]
437231
0
Changes in self-reported scores for depression
Query!
Assessment method [7]
437231
0
Patient Health Questionnaire (PHQ-9)
Query!
Timepoint [7]
437231
0
At baseline, then at Week 5, Week 8, Week 12 and Week 24 post intervention commencement
Query!
Secondary outcome [8]
437232
0
Changes in self-reported scores for anxiety
Query!
Assessment method [8]
437232
0
Generalised Anxiety Disorder Scale (GAD-7)
Query!
Timepoint [8]
437232
0
At baseline, then at Week 5, Week 8, Week 12 and Week 24 post intervention commencement
Query!
Secondary outcome [9]
437233
0
Changes in emotion regulation
Query!
Assessment method [9]
437233
0
Difficulties in Emotion Regulation Questionnaire (DERS)
Query!
Timepoint [9]
437233
0
At baseline, then at Week 5, Week 8, Week 12 and Week 24 post intervention commencement
Query!
Secondary outcome [10]
437234
0
Changes in sleep quality
Query!
Assessment method [10]
437234
0
Insomnia Severity Index (ISI)
Query!
Timepoint [10]
437234
0
At baseline, then at Week 5, Week 8, Week 12 and Week 24 post intervention commencement
Query!
Secondary outcome [11]
437235
0
Changes in HIV and other sexually transmitted infection risk behaviours
Query!
Assessment method [11]
437235
0
Substance Use and Sex Index (SUSI)
Query!
Timepoint [11]
437235
0
At baseline, then at Week 5, Week 8, Week 12 and Week 24 post intervention commencement
Query!
Secondary outcome [12]
437236
0
Subjective medication effects
Query!
Assessment method [12]
437236
0
Hood Mysticism Scale (HSM)
Query!
Timepoint [12]
437236
0
120 minutes post each ketamine administration
Query!
Secondary outcome [13]
437237
0
Changes in cognitive control and flexibility
Query!
Assessment method [13]
437237
0
Emotional N-back task
Query!
Timepoint [13]
437237
0
Baseline and 24 hours post third ketamine administration.
Query!
Secondary outcome [14]
437238
0
Changes in cognitive control
Query!
Assessment method [14]
437238
0
Emotional Stroop task
Query!
Timepoint [14]
437238
0
Baseline and 24 hours post third ketamine administration.
Query!
Eligibility
Key inclusion criteria
Adults presenting to outpatient drug treatment services seeking treatment for methamphetamine use disorder (MAUD) satisfying all of the following criteria:
Greater than or equal to 18 years of age
Able to provide informed consent
Willing and able to comply with all study requirements, as determined by the Principal Investigator
Meets DSM-5-TR diagnostic criteria for Current Stimulant Use Disorder – Amphetamine-Type Substance – as determined by the Principal Investigator and confirmed with Mini International Neuropsychiatric Interview (MINI)
Urine drug screen (UDS) point of care (POC) test positive for methamphetamine
Seeking treatment to cease or reduce methamphetamine use
If person of childbearing potential, willing to avoid pregnancy for study duration
Willing to register as a client of the St Vincent’s Hospital Sydney (SVHS) Stimulant Treatment Program (STP)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
DSM-5-TR diagnosis of current or past use disorder for ketamine or ketamine analogues as assessed by Mini International Neuropsychiatric Interview (MINI)
Prescribed or non-prescribed use of ketamine in the previous four weeks
Currently enrolled in another treatment trial of MAUD or clinical trial, which is likely to affect safety, data quality or may interfere with participation in this study, as determined by the Principal Investigator
Currently pregnant or breastfeeding, or planning on becoming pregnant during the course of the study
DSM-5-TR diagnosis of current psychotic disorder as assessed by the Principal Investigator including review of MINI
Current acute suicidality defined as ‘high risk’ using the C-SSRS-6 screener or as determined by the Principal Investigator
DSM-5-TR diagnosis of bipolar disorder as assessed by the Principal Investigator including review of MINI
Current DSM-5-TR diagnosis with other substance use disorders, moderate or severe, except tobacco, caffeine, or cannabis as assessed by the Principal Investigator including review of MINI. Opioid use disorder permitted if stable on opioid agonist treatment; OAT) (i.e. no dose changes for six weeks if on oral OAT and maximum of one missed dose/week. At least three months with no missed doses if on long-acting injectable)
History of sensitivity to ketamine or any other components of this product
If prescribed antidepressants, the participant must have been on a stable dose for four or more weeks
Contraindications to ketamine according to Australian Product Information:
Severe cardiovascular disease
Heart failure
Severe or poorly controlled hypertension
Recent myocardial infarction
History of stroke
Cerebral Trauma
Intracerebral mass or haemorrhage
Any other medical or psychiatric condition which in the opinion of the Principal Investigator would make participation hazardous. In particular, caution if severe liver, kidney or bladder disease, and also caution if elevated cerebrospinal fluid pressure, increased intraocular pressure, acute intermittent porphyria, seizures, hyperthyroidism, pulmonary or upper respiratory infection, intracranial mass lesions, a presence of head injury, globe injuries, or hydrocephalus.
Likely or planned surgery, travel, incarceration or other engagement during the study that may interfere with study participation
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
7/10/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
26761
0
St Vincent's Hospital (Darlinghurst) - Darlinghurst
Query!
Recruitment postcode(s) [1]
42810
0
2010 - Darlinghurst
Query!
Funding & Sponsors
Funding source category [1]
316884
0
Government body
Query!
Name [1]
316884
0
Australian Government Department of Health and Aged Care
Query!
Address [1]
316884
0
Query!
Country [1]
316884
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
St Vincent's Hospital Sydney
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
319132
0
None
Query!
Name [1]
319132
0
Query!
Address [1]
319132
0
Query!
Country [1]
319132
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
315649
0
St Vincent’s Hospital Human Research Ethics Committee
Query!
Ethics committee address [1]
315649
0
https://svhs.org.au/home/research-education/research-office
Query!
Ethics committee country [1]
315649
0
Australia
Query!
Date submitted for ethics approval [1]
315649
0
19/04/2024
Query!
Approval date [1]
315649
0
24/06/2024
Query!
Ethics approval number [1]
315649
0
2024/ETH00530
Query!
Summary
Brief summary
This study aims to determine the safety and feasibility of a combination of ketamine and cognitive behavioural therapy (ketamine-assisted therapy) for people with methamphetamine use disorder in an outpatient drug and alcohol treatment setting. There are currently no approved medications in Australia to help people manage, reduce, or stop their methamphetamine use; and psychotherapy is moderately effective. It is hoped that this study will help find out if ketamine-assisted psychotherapy (four sessions of cognitive behavioural therapy with three doses of ketamine, over a four-week period) is a safe and feasible treatment approach for methamphetamine use disorder.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
135366
0
Prof Nadine Ezard
Query!
Address
135366
0
St Vincent’s Hospital Sydney Alcohol and Drug Service 390 Victoria Street Darlinghurst NSW 2010
Query!
Country
135366
0
Australia
Query!
Phone
135366
0
+61 2 8382 1014
Query!
Fax
135366
0
Query!
Email
135366
0
[email protected]
Query!
Contact person for public queries
Name
135367
0
Kathryn Fletcher
Query!
Address
135367
0
Centre for Clinical Research on Emerging Drugs, University of New South Wales
Query!
Country
135367
0
Australia
Query!
Phone
135367
0
+61 02 93850333
Query!
Fax
135367
0
Query!
Email
135367
0
[email protected]
Query!
Contact person for scientific queries
Name
135368
0
Brendan Clifford
Query!
Address
135368
0
St Vincent’s Hospital Sydney Alcohol and Drug Service 390 Victoria Street Darlinghurst NSW 2010
Query!
Country
135368
0
Australia
Query!
Phone
135368
0
+61 457 474 854
Query!
Fax
135368
0
Query!
Email
135368
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
23958
Study protocol
[email protected]
23959
Informed consent form
[email protected]
23960
Ethical approval
[email protected]
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF